mgheaderbig
mgheaderbig

Advances in technology have improved healthcare providers' ability to rapidly diagnose patients at the point of care, screen for common conditions, and provide a variety of effective treatment options. Providers need to be aware of what innovations are available - or will become available in the near future. It is the purpose of Medgizmos to educate and inform healthcare providers regarding the latest and greatest technologies.

Slide 2

Latest Reviews

Image is not available
Connected Technology

Clarius mobile Ultrasound system facilitates POC diagnoses!

Image is not available
Medical Devices

Masimo Rad-Pulse Oximeter and Pediatric sensor!

Image is not available
Software/Applications

EM University educates providers about the new guidelines!

Slide 2

Latest Interviews/Webinars

Image is not available
Interview

Welch Allyn New 2021 Diagnostic Tools

Image is not available
Webinar

Coding 2021 New
Guidelines

Slide 3

Subscribe to receive notifications of our latest posts.

Slide 3

View our Summer 2021 Newsletter

Slide 3

New! Visit Our Podcast Page

Slide 3

New! Visit MDMtool.org

previous arrow
next arrow

Navigation

Home page sections include recent video reviews, a searchable list of all posts (reviews, webinars and interviews), and a list of post pages organized by topic.

Medgizmos

Is the “virtual medical home” of Andrew J. Schuman MD, who has been writing about medical technology and medical practice for over 30 years!

Update

July 28, 2021:  MDMtool.org online!   Masimo Rad-G Pulse Oximeter review now online.  Summer 2021 newsletter available for viewing .

FebriDx (Part 1)

s there a FebriDx in our future?

Physicians don’t want to overlook a serious bacterial infection that may cause prolonged illness, disability or death, yet we realize that antibiotics are overprescribed.  Over prescription encourages bacterial resistance, and over time if we are unable to curtail their use, our antibiotics may lose their efficacy.

How does a pediatrician determine if an infection is caused by bacteria or virus?  Clinical signs and symptoms often cannot distinguish between the two etiologies.   Medical technology can be helpful as rapid point of care (POC) assays can quickly identify patients with strep, influenza and RSV.   An infiltrate on CXR cannot distinguish viral vs bacterial pneumonia. Ancillary testing may be helpful.   An elevated WBC with a preponderance of neutrophils favors a bacterial etiology, as does an elevated c reactive protein (CRP), an acute phase reactant.  But wouldn’t be nice to have a quick, affordable, point of care that will help distinguish viral from bacterial infections?  Such an assay could provide reassurance and guide further workup.

In Britain, the National Institute for Health and Care Excellence (NICE) has developed straightforward guidelines for treating adults with lower respiratory tract infections.   A point of care CRP (none are CLIA waived in the US), is performed in adults with lower respiratory tract infections if a diagnosis of pneumonia has not been made. According to NICE, antibiotics are not indicated if CRP level are less than 20 mg/l, are recommended if levels exceed 100 mg/l, and may be considered if levels fall between these values if symptoms worsen.

A biotech company, RPS Diagnostics, has developed a novel test that combines a POC CRP assay with and assay for myxovirus resistance A protein (MxA) – an intracellular protein that becomes elevated in the presence of acute viral infection.  The test is called FebriDX, and  is not commercially available at this time.  The assay will undergo clinical trials in Britain and Canada and will eventually be evaluated by the Food and Drug administration for CLIA waived status in the USA.

In its present form FebriDx is a card based assay, that requires pipetting fingerstick blood into two separate areas of a test strip, closing the test cartridge and adding buffer solution to another area of the test card. Results are available in 10 minutes and indicate the likelihood of an infection being viral or bacterial based on the MxA and CRP results.

RPSDiagnostics has recently partnered with an Australian biotech company, Atomo Diagnostics, to modify FebriDx from a test card assay to a cartridge system that incorporates an in-built safety lancet, calibrated blood collection and delivery system, and integrated push-button buffer delivery mechanism to help prevent user-related errors and improve test performance (see FebriDx – part 2).

Can’t wait until this is available.

Subscribe

Subscribe

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!